World
Astra Eyes Extra Global Vaccine Trial as Questions Mount
- Additional test shouldn’t delay regulatory approvals, CEO says
- Different efficacy readouts for Oxford shot raised questions
This article is for subscribers only.
AstraZeneca Plc’s Covid-19 vaccine looks like it’s headed for an additional global trial as the drugmaker tries to clear up uncertainty and confusion surrounding favorable results in its current study.
The company wants the new test to confirm the 90% efficacy rate that the shot showed in a portion of an existing trial, Chief Executive Officer Pascal Soriot said. It’s favoring that option rather than adding an arm to a separate study that’s already underway in the U.S.